Dragana A. Kastratović
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Dragana A. Kastratović has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Srđan Z. Marković
4 shared publicationsLjubinka I. Nikolić
University Clinical Center of Serbia Belgrade Serbia
3 shared publications- Slobodan M. Jankovic
Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia
3 shared publications Emina S. Čolak
University Clinical Center of Serbia Belgrade Serbia
2 shared publications- Miloš Mojović
Center for Physical Chemistry of Biological Systems, BioScope Labs, Faculty of Physical Chemistry, University of Belgrade, 11158 Belgrade, Serbia
2 shared publications - Mira Vukovic
General Hospital, Valjevo, Serbia
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 12 (2) , 1648-1654
Drugs that must not be present in the donors's blood
Introduction: Transfusion is probably the most humane area of drug use, as donors freely give a substance that serves as medicine, and even one person can save many lives, especially of newborns. The aim of this work is to single out drugs whose use prevents a voluntary donor from donating blood within a certain period of time. If we talk about blood quality, we must take into account that the presence of metabolites or active substances of certain drugs is a potential cause of adverse reactions in the recipient. Bearing in mind the practical importance of this problem, the authors of this paper make their contribution in order to make transfusion safer. Topic: The significance of this topic lies in plasma-containing components, where donor-used drugs may be present. The division of drugs potentially harmful to the health of the transfusion recipient is related to the pharmacokinetics, side effects, and drug interactions. Whole blood is less frequently transfused. In clinical practice, components are applied, such as erythrocytes resuspended in OAS (SAGMANITOL). The drug is present in the whole blood, and by separating the cellular components, it becomes present in the plasma. The concentration of the drug in the stored blood component depends on the pharmacokinetic characteristics (t/2) of the drug, retention of the drug or metabolites in the donor's circulation. In fact, attention should be focused on the components that contain plasma: plasma, cryoprecipitate and platelet concentrates (PC). Overall, drug use should be divided into groups that temporarily exclude donors and groups that permanently exclude donors. Genetic vaccines are a new form of medicine that alarmingly points to the monitoring of distant side effects due to the presence of spike proteins. Conclusion: Drugs in transfusion as professional topic must be covered by local guides and SOPs of blood establishments and hospital blood banks. A regulation should be established defining drugs that are contraindications for donating. Modern analytical methods should be used as needed to detect the presence of drugs and their metabolites. Apart from the caution related to the presence of the drug in the blood/components, the biggest harm to the patient can be caused by the ambitious use of mRNA technology drugs and insufficient knowledge about this group of drugs. In medically unclear situations, the authors agree with the position of patient blood management that autotransfusion is the solution. The obligation for pharmacovigilance and hemovigilance should be legally regulated.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 12 (2) , 1648-1654
Open AccessDrugs that must not be present in the donors's blood
Introduction: Transfusion is probably the most humane area of drug use, as donors freely give a substance that serves as medicine, and even one person can save many lives, especially of newborns. The aim of this work is to single out drugs whose use prevents a voluntary donor from donating blood within a certain period of time. If we talk about blood quality, we must take into account that the presence of metabolites or active substances of certain drugs is a potential cause of adverse reactions in the recipient. Bearing in mind the practical importance of this problem, the authors of this paper make their contribution in order to make transfusion safer. Topic: The significance of this topic lies in plasma-containing components, where donor-used drugs may be present. The division of drugs potentially harmful to the health of the transfusion recipient is related to the pharmacokinetics, side effects, and drug interactions. Whole blood is less frequently transfused. In clinical practice, components are applied, such as erythrocytes resuspended in OAS (SAGMANITOL). The drug is present in the whole blood, and by separating the cellular components, it becomes present in the plasma. The concentration of the drug in the stored blood component depends on the pharmacokinetic characteristics (t/2) of the drug, retention of the drug or metabolites in the donor's circulation. In fact, attention should be focused on the components that contain plasma: plasma, cryoprecipitate and platelet concentrates (PC). Overall, drug use should be divided into groups that temporarily exclude donors and groups that permanently exclude donors. Genetic vaccines are a new form of medicine that alarmingly points to the monitoring of distant side effects due to the presence of spike proteins. Conclusion: Drugs in transfusion as professional topic must be covered by local guides and SOPs of blood establishments and hospital blood banks. A regulation should be established defining drugs that are contraindications for donating. Modern analytical methods should be used as needed to detect the presence of drugs and their metabolites. Apart from the caution related to the presence of the drug in the blood/components, the biggest harm to the patient can be caused by the ambitious use of mRNA technology drugs and insufficient knowledge about this group of drugs. In medically unclear situations, the authors agree with the position of patient blood management that autotransfusion is the solution. The obligation for pharmacovigilance and hemovigilance should be legally regulated.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 11 (2) , 1456-1461
Patient blood management: Team working between clinical transfusiology and clinical pharmacology
Introduction: Blood transfusion is the process of donating blood or blood components from a donor to a recipient of blood or blood components. Clinical pharmacology is a medical discipline created in the 20th century, that implies the most effective application of drugs, and it could be considered the culmination of all therapeutic procedures in medicine, or simply in the preservation of human health. Methods: Online search of pharmacology and transfusion literature was conducted using PubMed, Cochrane, Embase, and Scopus databases. Topic: Patient blood management (PBM) is a multidisciplinary multimodal patient-centered approach designed to minimize the use of allogeneic blood components in order to improve the clinical outcome of patient treatment. PBM consists of 3 main pillars with specific clinical goals. 1) First pillar: increasing red cell mass including clinical-pharmacological correction such as erythropoiesis stimulating agents (ESA) - iron and another drugs and optimizing the time for surgical intervention in relation to achieving the required hemoglobin value; 2) Second pillar: minimize blood loss through an adequate selection of surgical and anesthetic techniques, treatment with tranexamic acid (TXA) and autologous blood salvage, and the use of blood substitutes, 3) Third pillar: increasing the patient's tolerance to anemia through maximum improvement of pulmonary and cardiac function, optimizing ventilation, oxygenation and restrictive application of blood components. Clinically it is clear that clinical transfusiology and clinical pharmacology are part of each other originating from the fact that the use of classical medicine as well as the therapeutic use of blood achieves a therapeutic effect in order to improve the clinical status of the patient. Conclusion: Patient blood management implies health teams composed of clinical pharmacologist and clinical transfusiologist with other health care specialists making successful healthcare institutions. The most important thing is to monitor the development of new drugs, new transfusion solutions, and in this area, be especially careful when applying new drugs because of serious side effects that may occur. The agility of PBM is reflected in three pillars that must be harmonized and require continuous team education.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 11 (2) , 1456-1461
Open AccessPatient blood management: Team working between clinical transfusiology and clinical pharmacology
Introduction: Blood transfusion is the process of donating blood or blood components from a donor to a recipient of blood or blood components. Clinical pharmacology is a medical discipline created in the 20th century, that implies the most effective application of drugs, and it could be considered the culmination of all therapeutic procedures in medicine, or simply in the preservation of human health. Methods: Online search of pharmacology and transfusion literature was conducted using PubMed, Cochrane, Embase, and Scopus databases. Topic: Patient blood management (PBM) is a multidisciplinary multimodal patient-centered approach designed to minimize the use of allogeneic blood components in order to improve the clinical outcome of patient treatment. PBM consists of 3 main pillars with specific clinical goals. 1) First pillar: increasing red cell mass including clinical-pharmacological correction such as erythropoiesis stimulating agents (ESA) - iron and another drugs and optimizing the time for surgical intervention in relation to achieving the required hemoglobin value; 2) Second pillar: minimize blood loss through an adequate selection of surgical and anesthetic techniques, treatment with tranexamic acid (TXA) and autologous blood salvage, and the use of blood substitutes, 3) Third pillar: increasing the patient's tolerance to anemia through maximum improvement of pulmonary and cardiac function, optimizing ventilation, oxygenation and restrictive application of blood components. Clinically it is clear that clinical transfusiology and clinical pharmacology are part of each other originating from the fact that the use of classical medicine as well as the therapeutic use of blood achieves a therapeutic effect in order to improve the clinical status of the patient. Conclusion: Patient blood management implies health teams composed of clinical pharmacologist and clinical transfusiologist with other health care specialists making successful healthcare institutions. The most important thing is to monitor the development of new drugs, new transfusion solutions, and in this area, be especially careful when applying new drugs because of serious side effects that may occur. The agility of PBM is reflected in three pillars that must be harmonized and require continuous team education.
- Open Access
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 11 (1) , 1370-1376
Multidisciplinary teams in healthcare
Introduction: Making good teams are the base of management in general. A multidisciplinary medical team (MDT) is a group of health and care staff who are members of different professions and organizations (e.g. GPs, social workers, nurses), that work together to make decisions regarding the treatment of individual patients and service users. MDTs are engaged in both health and care settings. Methods: In this paper, the authors present information and views from valid professional-scientific sources (papers, books, brochures) about the basic principles and development of teams for medical healthcare that contribute to the development of the implementation of new concepts in health management (MH) for and against teamwork in this areas. Topic: A successful team relies on a well-composed human resource. Each of the member of team added their knowledge and skills to the prescribing process, so that decisions about the best therapy option, for example choice of antibiotics and dosages were made based on more evidence from the medical literature than if they were made by just one person. Clinical pharmacologists will certainly be necessary participants in such teams, because their knowledge of pharmacokinetics, side effects and efficacy of the selected drug is required. For successful personnel management in a team that is able to handle all the challenges and obstacles that multidisciplinary teamwork brings, appropriate education and professional skills of the main manager are required. An example of MDT in a modern therapeutic approach is the collaboration between hospital pharmacology and hospital transfusion. Teamwork has its advantages and disadvantages that a good leader can use or overcome. Conclusion: Multidisciplinary health teams often have the problem of immeasurable investments in order to achieve satisfactory therapeutic results. The formation of multidisciplinary teams in healthcare is a mandatory type of work in a successful healthcare institution. In addition to continuous medical education, it is desirable to introduce education for work in all positions in the health team. The most important goal of MDT is the well-being of the patient, which requires high ethical and professional qualities of the staff.
- 1 January 2024
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 11 (1) , 1370-1376
Open AccessMultidisciplinary teams in healthcare
Introduction: Making good teams are the base of management in general. A multidisciplinary medical team (MDT) is a group of health and care staff who are members of different professions and organizations (e.g. GPs, social workers, nurses), that work together to make decisions regarding the treatment of individual patients and service users. MDTs are engaged in both health and care settings. Methods: In this paper, the authors present information and views from valid professional-scientific sources (papers, books, brochures) about the basic principles and development of teams for medical healthcare that contribute to the development of the implementation of new concepts in health management (MH) for and against teamwork in this areas. Topic: A successful team relies on a well-composed human resource. Each of the member of team added their knowledge and skills to the prescribing process, so that decisions about the best therapy option, for example choice of antibiotics and dosages were made based on more evidence from the medical literature than if they were made by just one person. Clinical pharmacologists will certainly be necessary participants in such teams, because their knowledge of pharmacokinetics, side effects and efficacy of the selected drug is required. For successful personnel management in a team that is able to handle all the challenges and obstacles that multidisciplinary teamwork brings, appropriate education and professional skills of the main manager are required. An example of MDT in a modern therapeutic approach is the collaboration between hospital pharmacology and hospital transfusion. Teamwork has its advantages and disadvantages that a good leader can use or overcome. Conclusion: Multidisciplinary health teams often have the problem of immeasurable investments in order to achieve satisfactory therapeutic results. The formation of multidisciplinary teams in healthcare is a mandatory type of work in a successful healthcare institution. In addition to continuous medical education, it is desirable to introduce education for work in all positions in the health team. The most important goal of MDT is the well-being of the patient, which requires high ethical and professional qualities of the staff.
- Open Access
- 1 January 2021
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 8 (3) , 1073-1082
Benzodiazepines consumptions: Influence on traffic accidents
Introduction: Benzodiazepines belong to the group of anxiolytic sedatives and the most prescribed drugs in the world. Since these drugs have a potential for rapid anxiolytic effect and sedation, as well as driver capability impairment, there is a lack data of safety of benzodiazepines in traffic accidents. The aim: To make an assessment of the interconnection of time series of traffic accidents outcomes with time series of Benzodiazepine anxiolytic consumption in the Republic of Serbia. Methods: This paper is a part of IV phase academic study regarding the factors potentially affecting Benzodiazepine consumption and effects. We conducted a pharmaco-epidemiological time series analysis study of monthly sold Benzodiazepine anxiolytics in pharmacies and indicators of the crush road outcome on a monthly basis in the Republic of Serbia. The research was performed from January 2014 to December 2018. Results: Applying ARIMAX modeling we found a significantly link between DID of alprazolam with monthly total traffic accident, a high stochastic regression positive association of DID of Diazepam with the dependent variable monthly total traffic accident, the prediction of monthly fatalities of traffic accident or traffic accident with severe or slight injuries per total traffic accident we have demonstrated positive influence of DID of alprazolam in second-order autoregressive and moving average model with constant. In prediction of monthly fatalities traffic accident, a significant positive influence of DID of benzodiazepines (all together) in auto-regression model without constant was demonstrated. Conclusion: Consumption of both long-acting (over 12 h) and short-acting benzodiazepines together with all other causes highly determined the total number of traffic accidents on a monthly basis in 2014-2018 in the Republic of Serbia. An assessment of the interconnection of time series of traffic accidents outcomes with time series of Benzodiazepine anxiolytic consumption in the Republic of Serbia we found a significant positive influence of DID of benzodiazepines on traffic accidents outcomes. In total, all used benzodiazepines increase the number of fatal traffic accidents by 8.5 fold per month. Alprazolam additionally contributed with about ten percent (9.7%) to the frequency of traffic accidents on a monthly basis. Measures to prevent traffic accidents at all levels should be effective immediately in order to achieve positive results timely. The authors suggest that the great responsibility is raising awareness of compliance with traffic regulations with doctors who prescribe benzodiazepines.
- 1 January 2021
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 8 (3) , 1073-1082
Open AccessBenzodiazepines consumptions: Influence on traffic accidents
Introduction: Benzodiazepines belong to the group of anxiolytic sedatives and the most prescribed drugs in the world. Since these drugs have a potential for rapid anxiolytic effect and sedation, as well as driver capability impairment, there is a lack data of safety of benzodiazepines in traffic accidents. The aim: To make an assessment of the interconnection of time series of traffic accidents outcomes with time series of Benzodiazepine anxiolytic consumption in the Republic of Serbia. Methods: This paper is a part of IV phase academic study regarding the factors potentially affecting Benzodiazepine consumption and effects. We conducted a pharmaco-epidemiological time series analysis study of monthly sold Benzodiazepine anxiolytics in pharmacies and indicators of the crush road outcome on a monthly basis in the Republic of Serbia. The research was performed from January 2014 to December 2018. Results: Applying ARIMAX modeling we found a significantly link between DID of alprazolam with monthly total traffic accident, a high stochastic regression positive association of DID of Diazepam with the dependent variable monthly total traffic accident, the prediction of monthly fatalities of traffic accident or traffic accident with severe or slight injuries per total traffic accident we have demonstrated positive influence of DID of alprazolam in second-order autoregressive and moving average model with constant. In prediction of monthly fatalities traffic accident, a significant positive influence of DID of benzodiazepines (all together) in auto-regression model without constant was demonstrated. Conclusion: Consumption of both long-acting (over 12 h) and short-acting benzodiazepines together with all other causes highly determined the total number of traffic accidents on a monthly basis in 2014-2018 in the Republic of Serbia. An assessment of the interconnection of time series of traffic accidents outcomes with time series of Benzodiazepine anxiolytic consumption in the Republic of Serbia we found a significant positive influence of DID of benzodiazepines on traffic accidents outcomes. In total, all used benzodiazepines increase the number of fatal traffic accidents by 8.5 fold per month. Alprazolam additionally contributed with about ten percent (9.7%) to the frequency of traffic accidents on a monthly basis. Measures to prevent traffic accidents at all levels should be effective immediately in order to achieve positive results timely. The authors suggest that the great responsibility is raising awareness of compliance with traffic regulations with doctors who prescribe benzodiazepines.
- Open Access
- 1 January 2021
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 8 (2) , 1032-1040
Sunshine hours and utilization of benzodiazepines
Introduction: Benzodiazepines belong to the group of anxiolytic sedatives and the most prescribed drugs in the world. The authors conducted this pilot study based n large number of patients reports that they were less anxious and felt better overall by migrating to sunnier environments. Aim: We estimated the impact of the total sunshine hours per month on daily exposure of the population to Benzodiazepine anxiolytic on a monthly basis in the Republic of Serbia. Material and Methods: We conducted a retrospective academic IV phase study, which tested the correlation of time series of monthly sold Benzodiazepine anxiolytics in pharmacies and total sunshine hours per month in the Republic of Serbia, from January 2014 to May 2019. Results: According to the seasons, we did not find any difference in the increase of the population exposure to benzodiazepines. A difference was found between bromazepam consumption compared to cumulative monthly. Bromazepam consumption was negatively correlated with the cumulative monthly sunshine hours. The cutoff value for bromazepam was 131.45 cumulative monthly sunshine hours. Conclusion: This is the first pharmaco-epidemiologic study to prove that the population's exposure to benzodiazepines, in addition to the implicit health and economic effects on physicians' prescribing habits for these drugs, can be independently linked to the cumulative effects of monthly sunshine hours on the population. No difference in Benzodiazepine consumption was found in relation to the seasons (spring/summer vs autumn/winter). In months where sunshine hours was ≥135.45, the need for bromazepam was significantly reduced. Seasonal variation of climatic effects of total monthly sunshine hours is significantly correlated with the population's need for benzodiazepines with anxiolytic effects longer than 12 hours.
- 1 January 2021
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 8 (2) , 1032-1040
Open AccessSunshine hours and utilization of benzodiazepines
Introduction: Benzodiazepines belong to the group of anxiolytic sedatives and the most prescribed drugs in the world. The authors conducted this pilot study based n large number of patients reports that they were less anxious and felt better overall by migrating to sunnier environments. Aim: We estimated the impact of the total sunshine hours per month on daily exposure of the population to Benzodiazepine anxiolytic on a monthly basis in the Republic of Serbia. Material and Methods: We conducted a retrospective academic IV phase study, which tested the correlation of time series of monthly sold Benzodiazepine anxiolytics in pharmacies and total sunshine hours per month in the Republic of Serbia, from January 2014 to May 2019. Results: According to the seasons, we did not find any difference in the increase of the population exposure to benzodiazepines. A difference was found between bromazepam consumption compared to cumulative monthly. Bromazepam consumption was negatively correlated with the cumulative monthly sunshine hours. The cutoff value for bromazepam was 131.45 cumulative monthly sunshine hours. Conclusion: This is the first pharmaco-epidemiologic study to prove that the population's exposure to benzodiazepines, in addition to the implicit health and economic effects on physicians' prescribing habits for these drugs, can be independently linked to the cumulative effects of monthly sunshine hours on the population. No difference in Benzodiazepine consumption was found in relation to the seasons (spring/summer vs autumn/winter). In months where sunshine hours was ≥135.45, the need for bromazepam was significantly reduced. Seasonal variation of climatic effects of total monthly sunshine hours is significantly correlated with the population's need for benzodiazepines with anxiolytic effects longer than 12 hours.
- Open Access
- 1 January 2020
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 7 (3) , 976-982
Salviva®: Step forward in human saliva substitution
Introduction: Saliva is a product of salivary glands secretion that constantly soaks-moisturizes the teeth and mucous membranes of the oral cavity. Physiological roles of saliva are: maintaining humidity, lubrication and physiological cleaning of the oral cavity, enzymatic activity (beginning of digestion), bacteriostatic and bactericidal action, prevention of dental caries. Topic: The most serious health problem is the complete, permanent absence of saliva secretion , which is an absolute indication for daily use of an adequate preparation for moistening the oral cavity or saliva substitution. Salviva ® is sufficiently viscous and the content that can serve as natural saliva for 4 hours. 200 ml bottle is sufficient for daily patient needs and the production costs are low (0.25 EUR per unit for laboratory level volumes, excluding primary packaging costs). Conclusions: With the further innovative development of Salviva ® , it is possible to apply drugs with local and systemic effects, and thus treat the patient, which opens a completely new field of application of some drugs and reduces their side effects and unpleasant effects. The quality of life of patients as well as social functionality will be significantly improved, which is very important for the working population.
- 1 January 2020
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Hospital Pharmacology - International Multidisciplinary Journal
- Vol. 7 (3) , 976-982
Open AccessSalviva®: Step forward in human saliva substitution
Introduction: Saliva is a product of salivary glands secretion that constantly soaks-moisturizes the teeth and mucous membranes of the oral cavity. Physiological roles of saliva are: maintaining humidity, lubrication and physiological cleaning of the oral cavity, enzymatic activity (beginning of digestion), bacteriostatic and bactericidal action, prevention of dental caries. Topic: The most serious health problem is the complete, permanent absence of saliva secretion , which is an absolute indication for daily use of an adequate preparation for moistening the oral cavity or saliva substitution. Salviva ® is sufficiently viscous and the content that can serve as natural saliva for 4 hours. 200 ml bottle is sufficient for daily patient needs and the production costs are low (0.25 EUR per unit for laboratory level volumes, excluding primary packaging costs). Conclusions: With the further innovative development of Salviva ® , it is possible to apply drugs with local and systemic effects, and thus treat the patient, which opens a completely new field of application of some drugs and reduces their side effects and unpleasant effects. The quality of life of patients as well as social functionality will be significantly improved, which is very important for the working population.